Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer

Background Studies have demonstrated the efficacy of Palbociclib (CDK 4/6 inhibitor), Gedatolisib (PI3K/mTOR dual inhibitor) and PD0325901 (MEK1/2 inhibitor) in colorectal cancer (CRC), however single agent therapeutics are often limited by the development of resistance. Methods We compared the anti...

Descripción completa

Detalles Bibliográficos

Autores principales:	Cha Len Lee, Mattia Cremona, Angela Farrelly, Julie A. Workman, Sean Kennedy, Razia Aslam, Aoife Carr, Stephen Madden, Brian O’Neill, Bryan T. Hennessy, Sinead Toomey
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Taylor & Francis Group 2023-12-01
Colección:	Cancer Biology & Therapy
Materias:	colorectal cancer drug combinations palbociclib gedatolisib s6rp (s240/244)
Acceso en línea:	http://dx.doi.org/10.1080/15384047.2023.2223388
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!